Skip to Main Content

Author Details

Adam G Sowalsky
National Cancer Institute
2010
52
19
PMIDPaper TitleJournal TitlePublished Year
37816132Defining biology and recurrence risk in prostate cancers treated by neoadjuvant chemohormonal therapy.J Natl Cancer Inst2024
37205576Radiogenomic profiling of prostate tumors prior to external beam radiotherapy converges on a transcriptomic signature of TGF-β activity driving tumor recurrence.medRxiv2023
37790315Prediction of cancer treatment response from histopathology images through imputed transcriptomics.Res Sq2023
37725435Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models.J Clin Invest2023
37220531One toolkit to bring them all, and <i>in silico</i> analyze them.Clin Transl Discov2023
35078018Comment on: Intratumor heterogeneity and clonal evolution revealed in castration-resistant prostate cancer by longitudinal genomic analysis by Jing Li et al.Transl Oncol2022
35695870Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.Clin Cancer Res2022
36511483Defining cellular population dynamics at single-cell resolution during prostate cancer progression.Elife2022
36181613Progression of prostate cancer reprograms MYC-mediated lipid metabolism via lysine methyltransferase 2A.Discov Oncol2022
36179684Unpacking circulating tumor DNA lends insight into prostate cancer biology and the clonal dynamics of metastasis.Cancer Cell2022
35863822Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood.J Immunother Cancer2022
35227084Prostate-Specific Membrane Antigen Is a Biomarker for Residual Disease following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate Cancer.J Urol2022
35131873Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant Prostate Cancer.Cancer Res2022
35082166Modeling Androgen Deprivation Therapy-Induced Prostate Cancer Dormancy and Its Clinical Implications.Mol Cancer Res2022
33023952Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response.Clin Cancer Res2021
33575208Age and Tumor Differentiation-Associated Gene Expression Based Analysis of Non-Familial Prostate Cancers.Front Oncol2021
33516656AR-V7 biomarker testing for primary prostate cancer: The ongoing challenge of analytical validation and clinical qualification.Cancer Treat Res Commun2021
33899001EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer.Nat Cancer2021
33785256Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy.Eur Urol2021
34911936Androgen receptor and MYC equilibration centralizes on developmental super-enhancer.Nat Commun2021
34568716Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary Tumors.JCO Precis Oncol2021
34415294Comparison of approaches to transcriptomic analysis in multi-sampled tumors.Brief Bioinform2021
34168052A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes.Clin Cancer Res2021
33422353Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer.Eur Urol2021
32944614Battling the two-headed dragon of prostate cancer targeted therapy.Mol Cell Oncol2020
32054861A case report of multiple primary prostate tumors with differential drug sensitivity.Nat Commun2020
29229583Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer.Eur Urol Focus2019
31747605CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer.Cell Rep2019
31827286An intra-tumoral niche maintains and differentiates stem-like CD8 T cells.Nature2019
29748182A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening.Clin Cancer Res2018
30103901Molecular correlates of intermediate- and high-risk localized prostate cancer.Urol Oncol2018
30204063Are localized prostate cancer biomarkers useful in the clinical practice?Tumour Biol2018
30012673BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer.Cancer Res2018
29921690Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations.Cancer Res2018
30280090The Role of Immunohistochemical Analysis as a Tool for the Diagnosis, Prognostic Evaluation and Treatment of Prostate Cancer: A Systematic Review of the Literature.Front Oncol2018
30701023A comparison of prostate cancer bone metastases on <sup>18</sup>F-Sodium Fluoride and Prostate Specific Membrane Antigen (<sup>18</sup>F-PSMA) PET/CT: Discordant uptake in the same lesion.Oncotarget2018
29669286Platelets Promote Metastasis via Binding Tumor CD97 Leading to Bidirectional Signaling that Coordinates Transendothelial Migration.Cell Rep2018
28119368Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4.Clin Cancer Res2017
26936914ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.Clin Cancer Res2016
28133630PRECISION MANAGEMENT OF LOCALIZED PROSTATE CANCER.Expert Rev Precis Med Drug Dev2016
27272561Mutation Profiling Indicates High Grade Prostatic Intraepithelial Neoplasia as Distant Precursors of Adjacent Invasive Prostatic Adenocarcinoma.Prostate2016
27043282SOX9 drives WNT pathway activation in prostate cancer.J Clin Invest2016
25189356Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer.Mol Cancer Res2015
26473374Reciprocal regulation of Abl kinase by Crk Y251 and Abi1 controls invasive phenotypes in glioblastoma.Oncotarget2015
25906751Loss of Wave1 gene defines a subtype of lethal prostate cancer.Oncotarget2015
25320358Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.Clin Cancer Res2015
24449822Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.Clin Cancer Res2014
23204237Clonal progression of prostate cancers from Gleason grade 3 to grade 4.Cancer Res2013
23426182ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.J Clin Invest2013
21159665RalA function in dermal fibroblasts is required for the progression of squamous cell carcinoma of the skin.Cancer Res2011
  • 1 - 50 of 52

Recommended Authors

Sinja Taavitsainen
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 2018
Number of shared co-authors 6
Michael Sigouros
Caryl and Israel Englander Institute for Precision Medicine
Career Start Year 2017
Number of shared co-authors 12
Vincent Huang
Ontario Institute for Cancer Research
Career Start Year 2016
Number of shared co-authors 6
Natalie Kurganovs
Australian Prostate Cancer Research Centre Epworth
Career Start Year 2015
Number of shared co-authors 3
Joshua Armenia
Oncology R&D
Career Start Year 2013
Number of shared co-authors 17
Nicholas Erho
GenomeDx Biosciences Inc.
Career Start Year 2012
Number of shared co-authors 27
Julie Livingstone
University of California los angeles
Career Start Year 2011
Number of shared co-authors 11
Matti Annala
University of British Columbia
Career Start Year 2011
Number of shared co-authors 19
Mandeep Takhar
GenomeDx Biosciences Inc.
Career Start Year 2010
Number of shared co-authors 23
Himisha Beltran
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 45
Mohammed Alshalalfa
University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 26
Robert J Lonigro
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2007
Number of shared co-authors 19
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 8
Mitchell G Lawrence
Biomedicine Discovery Institute, Monash University
Career Start Year 2005
Number of shared co-authors 5
Thorsten Schlomm
Charite - University Hospital Berlin
Career Start Year 2004
Number of shared co-authors 8
Adam Foye
University of California San Francisco
Career Start Year 2003
Number of shared co-authors 16
Christopher E Barbieri
Weill Cornell Medical College
Career Start Year 2003
Number of shared co-authors 22
Scott A Tomlins
Rogel Cancer Center, University of Michigan Medical School ann arbor
Career Start Year 2003
Number of shared co-authors 27
Ashley E Ross
Northwestern University
Career Start Year 2003
Number of shared co-authors 28
Tarek A Bismar
University of Calgary Cumming School of Medicine, Rockyview General Hospital
Career Start Year 2002
Number of shared co-authors 15
Ladan Fazli
University of British Columbia
Career Start Year 2002
Number of shared co-authors 32
Michael Fraser
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2001
Number of shared co-authors 17
Jiaoti Huang
Duke University School of Medicine
Career Start Year 2000
Number of shared co-authors 23
Hayley C Whitaker
University College London
Career Start Year 1999
Number of shared co-authors 6
Srinivasan Yegnasubramanian
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 14
Xuhong Cao
Michigan Center for Translational Pathology.
Career Start Year 1999
Number of shared co-authors 21
Phillip G Febbo
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 16
Felix Y Feng
UCSF Medical Center-Mount Zion
Career Start Year 1997
Number of shared co-authors 48
Arul M Chinnaiyan
University of Michigan Medical School.
Career Start Year 1993
Number of shared co-authors 39
Mark A Rubin
University of Bern
Career Start Year 1990
Number of shared co-authors 40

Collaborators

Steven P Balk
Beth Israel Deaconess Medical Center and Harvard Medical School
Co-authored papers 19
Huihui Ye
College of Optical Science and Engineering, Zhejiang University
Co-authored papers 14
Rosina T Lis
National Cancer Institute
Co-authored papers 7
Peter S Nelson
Fred Hutchinson Cancer Center
Co-authored papers 7
Baris Turkbey
National Cancer Institute, National Institutes of Health
Co-authored papers 7
Changmeng Cai
Center for Personalized Cancer Therapy, University of Massachusetts Boston
Co-authored papers 6
Stephanie A Harmon
National Cancer Institute, National Institutes of Health
Co-authored papers 6
Peter L Choyke
National Cancer Institute, National Institutes of Health
Co-authored papers 6
Massimo Loda
Weill Medical College of Cornell University
Co-authored papers 5
Housheng Hansen He
Princess Margaret Cancer Center, University Health Network, University of Toronto
Co-authored papers 4
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Co-authored papers 4
Brian J Capaldo
Center for Cancer Research, National Cancer Institute
Co-authored papers 4
Elahe A Mostaghel
University of Washington
Co-authored papers 3
Maria J Merino
National Cancer Institute, National Institutes of Health
Co-authored papers 3
Ilsa Coleman
Fred Hutchinson Cancer Center
Co-authored papers 3
Eva Corey
University of Washington School of Medicine
Co-authored papers 3
Eliezer M Van Allen
Dana-Farber Cancer Institute
Co-authored papers 3
Matthew L Freedman
Dana-Farber Cancer Institute
Co-authored papers 3
Shuai Gao
Center for Personalized Cancer Therapy, University of Massachusetts Boston
Co-authored papers 2
Mark M Pomerantz
Dana-Farber Cancer Institute
Co-authored papers 2
Lawrence D True
University of Washington School of Medicine
Co-authored papers 2
Johann S de Bono
The Institute for Cancer Research
Co-authored papers 2
Anjali V Sheahan
Dana-Farber Cancer Institute
Co-authored papers 2
Adeboye O Osunkoya
Emory University School of Medicine
Co-authored papers 2
Stephen R Plymate
University of Washington
Co-authored papers 2
Bruce Montgomery
Fred Hutchinson Cancer Center, University of Washington
Co-authored papers 2
Leigh Ellis
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 2
Wei Li
Co-authored papers 2
Adam Sharp
The Institute for Cancer Research
Co-authored papers 2
Yuzhuo Wang
University of British Columbia
Co-authored papers 1
Release 1.2